1. Bone marrow stroma partially protects multiple myeloma and AML cell lines from tipifarnib- and bortezomib-induced cell death. 8226/S myeloma cells were treated with the indicated concentrations of bortezomib (A), tipifarnib (B), or the combination (C) for 2...
Bone marrow stroma partially protects multiple myeloma and AML cell lines from tipifarnib- and bortezomib-induced cell death. 8226/S myeloma cells were treated with the indicated concentrations of bortezomib (A), tipifarnib (B), or the combination (C) for 24 hours. Cells were treated either in suspension culture (suspension) or after adhesion to HS-5 stromal cells (adhered). The HS-5 stroma line (stroma) expresses GFP in a stable fashion. Myeloma cells were distinguished from stromal cells in coculture by using flow cytometry with gating on GFP+ and GFP− populations. D, U937 leukemia cells were treated and analyzed as in (C). Cell death was determined by staining with Annexin V/FITC and 7-amino actinomycin-D as described in Materials and Methods. Percent live cells are relative to tumor cells treated with control media only. Combined from three independent experiments (A-D). Columns/points, mean; bars, SE.
Niranjan Yanamandra et al. Clin Cancer Res 2006;12:
©2006 by American Association for Cancer Research